Collegium Pharmaceutical Inc (COLL)

Gross profit margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Gross profit	US$ in thousands	377,344	326,169	209,488	150,617	179,836
Revenue	US$ in thousands	631,449	566,767	463,933	276,868	310,016
Gross profit margin		59.76%	57.55%	45.15%	54.40%	58.01%

December 31, 2024 calculation

Gross profit margin = Gross profit ÷ Revenue
= $377,344K ÷ $631,449K
= 59.76%

The gross profit margin of Collegium Pharmaceutical Inc has displayed fluctuations over the past five years. In December 2020, the gross profit margin stood at 58.01%, reflecting a strong profitability level. However, there was a decline in the margin to 54.40% by December 2021, indicating a reduction in the company's ability to generate profits from its core operations.

Subsequently, by December 2022, the gross profit margin decreased further to 45.15%, suggesting potential challenges in managing production costs or pricing strategies during that period. The year 2023 saw an improvement in the margin to 57.55%, indicating a positive trend in profitability.

Finally, by December 2024, the gross profit margin increased to 59.76%, surpassing the initial level in 2020. This improvement suggests effective cost management, pricing strategies, or potentially higher sales revenues contributing to stronger profitability.

Overall, Collegium Pharmaceutical Inc's gross profit margin has experienced varying levels over the years, highlighting the importance of continuous monitoring and strategic decision-making to maintain and enhance profitability in the pharmaceutical industry.